Chronic kidney disease (CKD) is highly prevalent in patients with diabetes or hypertension in primary care. A shared care model could improve quality of care in these patients
INTRODUCTION
The high and rising prevalence of chronic kidney disease (CKD) -which amounts to 13% in the general population in the US and 7% in primary care in the UKplaces a burden on healthcare facilities. 1, 2 Of the risk factors contributing to CKD, diabetes and hypertension are the most common. 3 CKD can progress to end-stage renal disease. The awareness of CKD is predominantly fostered by the recognition that it is an important risk predictor for coronary events and cardiovascular mortality. 4, 5 Timely intervention that is directed at cardiovascular risk factors can decrease the loss of renal function and the incidence of cardiovascular disease. [6] [7] [8] Guidelines provide recommendations for treatment of CKD; 9, 10 however, treatment targets are often not met. [11] [12] [13] There is a significant evidence gap in how to best organise the care for patients with CKD.
14 A multidisciplinary approach has been proposed; 15 shared care between primary and secondary care has been successful in the treatment of other chronic conditions. 16 Observational studies on shared care for patients with CKD show promising results, 17 but the effectiveness of shared care for patients with CKD has not yet been proved in randomised trials. 18 This study developed a shared care model for patients with CKD in primary care in which the nurse practitioner played a central role and a nephrologist and a nephrology nurse could be consulted. In a cluster randomised controlled trial the study tested whether the model led to improved quality of care in patients with CKD and diabetes or hypertension. Lowering of blood pressure was the primary outcome.
METHOD Setting
The study involved nine general practices (54 231 patients) that are part of the Academic Practice-based Research Network of Radboud University Nijmegen Medical Centre in The Netherlands. 19 Usual care for patients with diabetes and hypertension in these practices is given in a structured setting with the help of nurse practitioners. Patients with diabetes or hypertension are seen every 3 months. Once a year an extensive control including renal function monitoring is performed according to the national evidence-based practice guidelines. 20, 21 Blood pressure measurements are performed according to a protocol, which requires a rest period and noting the mean of two measurements.
Adult patients (aged >18 years) who were treated for hypertension or type 2 diabetes mellitus by their GP and had an estimated glomerular filtration rate (eGFR) measurement of <60ml/min/1.73m 2 were
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a cluster randomised controlled trial included. GPs were informed which patients lacked the annual information on renal function, so they could have them tested and include them if an eGFR of <60ml/ min/1.73m 2 was newly found. Exclusion criteria were:
• serious medical or psychiatric conditions;
• drug or alcohol abuse;
• specialist CKD care in the last year;
• inability to understand Dutch (including cognitive disorders); and
• participation in another intervention trial.
Eligible patients were invited to take part in the study when they visited the practice for a regular consultation until a minimum of 20 and a maximum of 28 patients per practice were recruited. Patients were included if they had given written informed consent and if a second eGFRmeasurement was still <60ml/min/1.73m
Randomisation was carried out at the general practice level because the intervention involved changes to the practice organisation. Practices were stratified by the mean blood pressure of all eligible patients and then randomly allocated to intervention or control group. In the control practices, patients were identified and included at the start of the study. To avoid bias by study inclusion, patients were asked to give written informed consent only at the time of the final measurement at the end of the trial; their GPs and nurse practitioners were informed of the patient's study inclusion or exclusion status at that time.
To show a clinically relevant difference in the decline of blood pressure of 5 mmHg (standard deviation of blood pressure difference 10 mmHg, a = 0.05, b = 0.20, and intracluster correlation coefficient (ICC) 0.03) the study was powered to contain nine practices with 25 patients per practice.
Intervention
The multifaceted intervention consisted of the training of professionals, structured care by nurse practitioners, and the opportunity to ask advice from a nephrology team. In spring 2008, nurse practitioners and GPs of intervention practices were trained by a nephrology team. Blood pressure measurement and treatment, proteinuria, cholesterol lowering, bloodglucose management, and lifestyle advice were the main issues. A protocol, based on the Kidney Disease Outcomes Quality Initiative (KDOQI) guideline, was provided with treatment goals and treatment advice. 10 During the following intervention year, nurse practitioners received two extra training sessions on treatment of hyperparathyroidism and anaemia. The nurse practitioner saw patients every 3 months for a 20-minute consultation, in which blood pressure treatment was the main aim. Patients and nurse practitioners decided together which other treatment goals were to be prioritised. GPs supervised the consultation afterwards. GPs and nurse practitioners could, if necessary, consult a nephrology team in a protected digital environment.
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Outcome
Lowering of blood pressure was the primary outcome and was ascertained according to the difference between the usual blood pressure measurement at baseline and the study blood pressure measurement after 1 year. At the end of the trial, blood pressure and the number of patients meeting the blood pressure target (130/80 mmHg) were compared between the control and intervention groups. Other quality-of-care variables were kidney-disease measures and the number of patients that reached the treatment goals. Additionally, functional status and the use of angiotensin system inhibitors and lipid-modifying agents were measured. The number of consultations with the nephrologist and the number of referrals were described.
At baseline, the nurse practitioner collected data in the intervention group. After 1 year the same measurements were performed in patients in both intervention and control practices. Study blood pressure was measured with an oscillometric device (Stabil-O-Graph). After a 5-minute rest,
How this fits in
Chronic kidney disease (CKD) is highly prevalent in patients with diabetes or hypertension in the primary care setting and leads to a large rise in cardiovascular risk. Although CKD guidelines are clear, implementation in primary care is poor, partly because of lack of confidence from GPs and partly because of lack of time. A shared care model between the GP, nurse practitioner, and a nephrology team is an effective way to reduce blood pressure in patients presenting to primary care who have CKD and diabetes or hypertension. Given the societal burden of CKD, this model may prove to be cost effective in lowering cardiovascular morbidity and mortality.
three measurements were taken with the patient in a sitting position; the mean of the last two measurements was used for analysis. In patients with atrial fibrillation, blood pressure was measured manually with a sphygmomanometer. The latest noted usual blood pressure measurement before inclusion was used as the baseline value for blood pressure.
Clinical 23 Calcium levels were corrected for albumin levels. Haemoglobin was measured on a Sysmex XE-2100 instrument. Albuminuria was defined as an albumin:creatinine ratio of ≥2.5mg/mmol or ≥3.5mg/mmol in male or female patients respectively.
COOP-WONCA charts were used to obtain additional information about the patient's functional capacity. 24 
Statistical analysis
Descriptive analyses were used to describe the characteristics of the patients in both groups. As a result of the hierarchical structure of the study (patient nested within practices), multilevel analyses were performed that took account of the variability associated with each level of nesting.
A random intercept model with other variables that were fixed was used. For dichotomous variables, a multilevel logistic model was performed. Blood pressure change between intervention and control group was analysed by analysis of covariance with the follow-up blood pressure measurement as an outcome and the baseline blood pressure measurement (last noted blood pressure in the patient file) as a covariate. As the number of practices was relatively small, a cluster-level analysis was performed by analysing summary measures from each cluster as a sensitivity analysis. 25 The ICC was calculated from preintervention blood pressure data from both intervention and control group. SAS Proprietary Software 9.2 was used for all analyses and multilevel analyses were performed with PROC MIXED for continuous outcomes and PROC GLIMMIX for dichotomous variables. Figure 1 shows a flowchart of participating practices and patients. Five intervention practices included 16, 12, 20, 23 , and 28 patients respectively; four control practices included 6, 23, 19, and 27 patients. Nine patients from four practices in the intervention group did not finish the trial: two died (of lung carcinoma and heart failure), three stopped because their general condition worsened, and four no longer wished to come for extra control visits. One patient in the control group was excluded from the analysis because of extreme blood pressure values that were considered to be invalid measurements (270/170 mmHg). Usual systolic blood pressure at baseline did not differ between the intervention and control groups, whereas diastolic blood pressure was lower in the intervention group (Table 1) . The decrease in systolic blood pressure in the intervention group was 8.1 mmHg (95% confidence interval [CI] = 4.8 to 11.3) compared with 0.2 mmHg (95% CI = −3.8 to 3.3) in the control group ( Table 2 ) . The decrease in diastolic blood pressure did not differ between intervention and control group. The ICC was 0.11 for systolic blood pressure and 0.15 for diastolic blood pressure. Blood pressure after 1 year was lower in the intervention group than in the control group: systolic blood pressure was 8.2 mmHg (95% CI = 3.6 to 12.9) lower, diastolic blood pressure was 4.7 mmHg (95% CI = 1.1 to 8.4) lower (Appendix 1) The number of patients that reached the treatment goal for systolic blood pressure in the intervention group (44.4%) was higher than in the control group (21.6%) (odds ratio [OR] 2.9 [95% CI = 1.4 to 5.8]; P = 0.003). For diastolic blood pressure these percentages were 71.1% and 50.0% respectively (OR 2.5; 95% CI = 1.3 to 4.7; P = 0.007) ( Table 2 ). More patients in the intervention group received renin-angiotensin system inhibitors, lipidlowering drugs, and vitamin D than patients in the control group. Laboratory values did not differ between the intervention and control groups, with the exception of PTH, which was lower in the intervention group (Table 2) .
RESULTS
During the intervention, cholesterol and low-density lipoprotein (LDL) levels decreased in the intervention group, parallel with an increase in the use of lipid-lowering drugs (Appendix 2).
In 31 patients in the intervention group, 50 consultations were performed between the GP and nephrologist; none of these resulted in a referral. In the intervention group, two patients were referred to a nephrologist; in the control group, one patient was referred.
DISCUSSION
Summary
The shared care model for patients with CKD and diabetes or hypertension leads to a significant and clinically relevant systolic lowering of blood pressure in the intervention group compared with the control group; in addition, there was also a better achievement of blood pressure targets along with increased use of renin-angiotensin system inhibitors. The intervention also led to lower PTH levels, along with an increased use of vitamin D, as well as leading to an increased use of lipid-lowering drugs. Although LDL cholesterol decreased in the intervention group, LDL levels at the end of the study did not differ between the intervention and control groups.
It is promising that blood pressure targets were better met in the shared care practices, because a lower blood pressure is associated with better patient outcome. 6 Hypertension management is generally recognised as a primary care task, but blood pressure management in patients with CKD in primary care is not as effective as it is in nephrology. 26 Underlying factors are that the GP's confidence in treating CKD is lower than in treating diabetes and hypertension, and that blood pressure targets in CKD are often regarded with scepticism. 27, 28 A discussion is ongoing with regard to optimal blood pressure targets. 29 Systolic blood pressure of <120 mmHg is associated with stroke and diastolic blood pressure of <60 mmHg is associated with increased mortality in older people who are frail. 30, 31 Nephrologists could be of help in the titration of antihypertensive agents.
Albuminuria did not change during the study. This was due to the fact that albuminuria treatment goals had been met Heart failure, % 3 5
Transient ischaemic attack, % 6 6
Cerebrovascular accident, % 6 10
Peripheral artery disease, % by a large number of patients at baseline. In a sub-analysis no albuminuria differences between patients with and without diabetes were found.
Strengths and limitations
A strength of the study is that it used a cluster randomised trial design. Usual care for patients with diabetes and hypertension in the practices was already well organised, which makes the additive value of the shared care model robust. Baseline blood pressure values were at a relatively low level; in practices with less-favourable baseline blood pressure levels, it may be possible to see even more improvement. Potential bias in the usual-care group was reduced by informing these patients, GPs, and nurse practitioners about the study at the end of the trial.
The setting in research practices enabled retrospective collection of usual blood pressure measurements to serve as baseline measurements for the control group. A further strength is that, before entry, participants had had two consecutive measurements of eGFR <60ml/min/1.73m 2 to confirm a diagnosis of CKD.
Several limitations need to be mentioned. The first is a potential selection bias: although identified at the beginning of the trial, patients in the control group were asked for their informed consent 1 year after randomisation of their practice took place.
As a second limitation, it should be mentioned that a pragmatic recruitment procedure was followed: when the maximum number of patients in one cluster was reached, the inclusion in that practice was stopped. This may have caused a selection of patients who were relatively healthy to adhere to the control visits. On the other hand, not all practices reached the required minimum of 20 patients.
A third limitation is that it was necessary to rely on usual blood pressure measurements to serve as baseline values. It is well known that usual blood pressure measurements lead to higher results than blood pressure measurements in a study setting. 32 The fact that the usual blood pressure measurement in the control group did not differ from the study blood pressure levels at the end of the study reduces concerns about comparability of usual and study blood pressure measurements in this trial.
A further point to be noted concerns generalisability. The population in this study was mainly white, so the results are not representative of a population with a greater proportion of patients of other ethnicities or racial groups, who may have different blood pressure outcomes.
Comparison with existing literature
The effect of structured care by nurses was assessed in an observational study by Richards et al. 33 Patients with CKD were enrolled in a disease management programme. Blood pressure decreased with 9/5 mmHg, but only in patients without diabetes or proteinuria. In secondary care, several studies have been performed on the nurses' role in managing patients with CKD, with varying success. A study on older patients referred to a multidisciplinary care clinic with a nephrologist and a specialised nurse showed a 50% reduction of the risk for all-cause mortality in an observational British Journal of General Practice, December 2013 e803 C09 agents acting on the RAAS system n/a n/a n/a n/a n/a study. 34 In a comparison between additional intensive nurse-practitioner support and nephrologist care, the blood pressure decrease in the intervention group was 3/2 mmHg more (P<0.001) than in the control group. 35 However, in a randomised trial in which patients were randomly assigned to a nurse-coordinated team in secondary care, or to usual care in general practice, no effect on cardiovascular risk-factor control or on clinical end points was found. 36 The opportunity to ask advice from a nephrologist has been studied in a shared care system in the UK. 17 Patients were treated in primary care that was sustained by continuous feedback from nephrologists on the laboratory and blood pressure results. Blood pressure decreased and the prescribing of renin-angiotensin system inhibitors increased.
In summary, the existing literature endorses this study's findings that structuring care for patients with CKD is beneficial in reducing blood pressure. However, study designs were mainly observational with, consequentially, low levels of evidence. Cluster randomised trials like this are scarce; the Quality Improvement in CKD study (a cluster randomised trial to compare quality-improvement interventions to lower systolic blood pressure in CKD in primary care) showed that audit-based education led to blood pressure lowering of 2.4 mmHg.
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Implications for practice It is promising that an intervention of shared care showed lowering of systolic blood pressure during a 1-year intervention, even in practices that already had a wellstructured care for patients with diabetes or hypertension. Statements on more-relevant endpoints, such as cardiovascular events and hospital admissions, would need larger and longer cluster randomised trials.
Future studies should provide information on cost effectiveness. CKD has a high financial burden. This model of care aims to provide optimal care at the cheapest level possible, and may be cost-effective in lowering cardiovascular morbidity and mortality but this requires future study.
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